Quick Answer
Cadrenal Therapeutics, Inc. reported R&D Expense of $4.10 million for fiscal year 2025.
Cadrenal Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $4.10M | -2.5% |
| 2024 | $4.21M | +3.0% |
| 2023 | $4.08M | +36.0% |
| 2023 | $3.00M | +663.6% |
| 2022 | $392.9K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $688.5K | -12.3% | -36.1% |
| June 30, 2025 | $1.08M | -14.1% | -35.4% |
| March 31, 2025 | $1.67M | +165.2% | +112.6% |
| September 30, 2024 | $784.6K | +221.6% | -37.4% |
| June 30, 2024 | $1.25M | +420.3% | +99.3% |
| March 31, 2024 | $629.0K | -80.6% | +157.9% |
| September 30, 2023 | $243.9K | +332.6% | +1.2% |
| June 30, 2023 | $241.0K | — | -92.6% |
- Cadrenal Therapeutics, Inc. showed a decrease of -2.5% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, Cadrenal Therapeutics, Inc.’s r&d expense has grown by 943.7% (from $392.9 thousand to $4.10 million).
- The most recent figure is from Cadrenal Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: